National Center of Pulmonology of the RA Ministry of Health SNCO

Your second breath

Naira Khachatryan

Acting Director

World Health Organization Europe Office Research Advisor



2019թ. - Regional technical consultation meeting: Transitioning to the latest WHO Policy Guidance on drug-resistant tuberculosis (DR-TB)”, Kiev

2019թ. - Regional Meeting for Eastern Europe and Central AsiaAIDS and Tuberculosis in Eastern Europe and Central Asia: time to face the facts, Istanbul

2019թ. - Dubai AUE, July 8-11 Global Consultation on best practice in MDRTB care  Harvard medical school in Dubai, workshop

2019թ. - 6 th  MSF regional TB Symposium Tashkent, Uzbekistan

2018թ. - 49 th UNION WORLD CONFERENCE ON LUNG HEALTH, Hague   Netherlands

2017թ. - 48th UNION WORLD CONFERENCE ON LUNG HEALTH, Guadalajara Mexico


2016թ. - 5 th  MSF regional  TB Symposium. Tbilisi Georgia ‘’Improving treatment outcomes through a patient cantered approach and access to new treatments’’ presentation: V-DOT implementation in DRTB program

2015թ. - 4 th TB Symposium. MSF /MOH “New treatments and approaches to tuberculosis”, Yerevan Armenia

2014թ. - Participation in Pan-Russian International Scientific -practical TB conference. Moscow RF , presentation of CU  Bdq Best Practice in Armenia

2014թ. - Field Management Training, MSF, Armenia

2014թ. - WHO workshop on Results-based Management for TB prevention , Care and Control , Yerevan Armenia

2013թ. - MSF International Workshop on management of non-tuberculosis mycobacterial  , Phnom Penh, Cambodia

2012թ. - MSF International Workshop of DR TB in  Armenia, facilitator

2012թ. - Training /observation  ”Sputnik’’ sub- program in circle of the DR TB management, Tomsk, RF in collaboration with  PHD

2010թ. - MSF International Workshop of DR TB in Mumbai, India

2007թ. - STI/HIV, TB harm reduction and Management, TB Treatment of the patients with STI/HIV, Armenia


Գիտական հրապարակումներ և շնորհանդեսներ

  1. Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia  .Article in The International Journal of Tuberculosis and Lung Disease 22(7):766-772 · July 2018 with 5 Reads DOI: 10.5588/ijtld.17.0840
  2. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study     Published: February 13, 2018DOI://
  3. Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges European Respiratory Journal 2016; DOI: 10.1183/13993003.00705-2016
  4. Discordances between TST and IGRA to detect latent tuberculosis infection in pediatric contacts of drug-resistant tuberculosis patients. 48th UNIOIN  World Conference on Lung Health, 11-14 October 2017, Guadalajara,  Mexico  Abstract and electronic poster presentation
  5. Twelve-month sputum culture reversion among patients receiving MDR-TB treatment with Bedaquiline and Delamanid  48th UNIOIN World Conference on Lung Health, 11-14 October 2017  Abstract and oral presentation
  6. Delivering twice daily Delamanid: the video-DOT experience of the Armenian National Tuberculosis Program  
  7. Is the shorter MDRTB regimen suitable for Eastern Europe? The example of Armenia  49th  UNIOIN World Conference on Lung Health,  October 2018   Abstract and poster  presentation
  8. High prevalence of infection and low incidence of disease in child contacts of patients with drug-resistant tuberculosis: a prospective cohort study,  published  Arch Dis Child. 2019 Jul; 104(7): 622–628 // PMC6589461  PMID: 3052317
  9. Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis.

Emerg Infect Dis 2019 05;25(5):936-943 May 2019


  1. Bedaquiline and Repurposed Drugs for Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: How Much Better Are They?


Am J Respir Crit Care Med 2018 11;198(9):1228-12312 Médecins Sans Frontières Paris, France. November 2018

  1. Culture conversion at six months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis. Article in Clinical Infectious Diseases · November 2019